about/contact | site map | advertising


RCTI receives RCT1938 patents
Article Thumbnail ImageJuly 30, 2012 -- Biopharmaceutical company Radiation Control Technologies (RCTI) has been granted an exclusive license to two patents from the U.S. National Institutes of Health.

To view the remainder of this article, and other exclusive content, you must first sign-in or register using the options below.
(Helptag:PaywallArticleLoginMessage)
Member Sign In:
  MemberID or E-mail Address:
  Password:
(?)
Forgot your password? Click here.

View our privacy policy
New AuntMinnie.com Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • OnLine CMe/CE
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
    		•

    The license covers the composition and uses of the company's RCT1938 agent worldwide as a radiosensitizer to treat cancer and to treat or prevent radiation exposure in humans, RCTI said.

    RCTI is entering into advanced preclinical testing of RCT1938 as an adjuvant for radiotherapy and is seeking federal grants and contracts to develop RCT1938 as a radiation medical countermeasure.

    RCT1938 is derived from a chemical class that has been proven safe in clinical trials, according to the company.

    || About || Advertising || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2013 || Education || Equipment Classifieds || Facebook || Forums || Home || Links || Marketplace || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2012 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2013 AuntMinnie.com. All Rights Reserved.